Jounce Therapeutics earns clinical milestone payment under the CCR8 exclusive license agreement with Gilead Sciences, Inc. Pharmaceutical Investing
U.S. Food and Drug Administration Approves Vemlidy® for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients Pharmaceutical Investing
Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022 Pharmaceutical Investing
Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease Pharmaceutical Investing
